Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Autor: Tang GQ; UCB Pharma, Cambridge, MA, United States., Tang Y; UCB Pharma, Cambridge, MA, United States., Dhamnaskar K; Ra Pharmaceuticals, Cambridge, MA, United States., Hoarty MD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Vyasamneni R; Ra Pharmaceuticals, Cambridge, MA, United States., Vadysirisack DD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ma Z; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Zhu N; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Wang JG; UCB Pharma, Cambridge, MA, United States., Bu C; UCB Pharma, Cambridge, MA, United States., Cong B; UCB Pharma, Cambridge, MA, United States., Palmer E; UCB Pharma, Cambridge, MA, United States., Duda PW; UCB Pharma, Cambridge, MA, United States., Sayegh C; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ricardo A; Ra Pharmaceuticals, Cambridge, MA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Sep 25; Vol. 14, pp. 1282155. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.

Autor: Fichtner ML; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America.; Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, United States of America., Hoarty MD; UCB Pharma, Cambridge, Massachusetts, United States of America., Vadysirisack DD; UCB Pharma, Cambridge, Massachusetts, United States of America., Munro-Sheldon B; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America., Nowak RJ; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America., O'Connor KC; Department of Neurology, Yale School of Medicine, New Haven, Connecticut, United States of America.; Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut, United States of America.

Publikováno v: PloS one [PLoS One] 2022 Mar 15; Vol. 17 (3), pp. e0264489. Date of Electronic Publication: 2022 Mar 15 (Print Publication: 2022).